Julie Allen is a Partner in Proskauer's Corporate Department and a co-head of the Capital Markets Group.
Julie’s practice focuses on general corporate and securities matters. She represents both underwriters and issuers in initial public offerings and follow-on equity offerings. Her experience also includes Rule 144A debt offerings, both as counsel to issuers and to initial purchasers. Julie's practice also includes mergers and acquisitions, particularly transactions involving public companies. She represents buyers and sellers, activist stockholders, boards of directors and financial advisors in mergers, acquisitions, recapitalizations and tender offers. Julie also regularly counsels public companies and their affiliates regarding disclosure, governance, Sarbanes-Oxley and other securities law and compliance issues.
Julie serves as the Co-Chair of Proskauer's New Business Committee and Chair of its Corporate Department Opinion and Audit Letter Committees.
Bernard Cooney is Managing Director at UBS.
James L. Elrod Jr
Jim is a Vestar Managing Director. He joined the firm in 1998, bringing with him years of operational experience in the healthcare sector.
He was Executive Vice President at Physicians Health Services, where he also served as corporate CFO, CEO of the New York and New Jersey subsidiaries, and President of the New Jersey insurance subsidiary.
Before that, he was a partner at Dillon, Read & Co., a private investment bank, where he created and ran the firm’s healthcare investment group, and served as co-head of equity issuance.
Robin Feiner is a Senior Counsel in Proskauer's Corporate Department and a member of the Capital Markets Group.
Robin expands the firm’s equity capital markets global platform with her extensive industry insight and experience with IPOs and other equity transactions. She has worked with investment bankers and capital markets advisers, as well as executive officers, in planning and executing IPOs, follow-ons, block trades and other equity financings across a broad range of industries, including industrials, health care, technology, consumer, financial institutions, real estate, energy and power.
Robin has worked on more than one hundred global IPOs, including billion dollar offerings of American Water Works, MasterCard and Loews Corporation/Carolina Group. Other representative IPOs include Installed Building Products, WCI Communities, Norwegian Cruise Lines, Liposcience, Marathon Petroleum, GasLog, Verastem, Mattress Firm, American Capital Mortgage, Box Ships, GEVO, Mead Johnson Nutrition, SPACS (including Lazard and Perella), Genpact, IHS, GFI Group, Calamos Asset Management, Willis Group, ExpressJet and LeapFrog Enterprises.
Frank Lopez is a Partner in the Corporate Department and co-head of the Global Capital Markets Group. His primary focus is on capital markets transactions, whereby he represents investment banks, sponsors and issuers in public and private debt and equity offerings, often in the context of domestic and cross-border leveraged buyouts, refinancings and restructurings. Frank’s practice also includes corporate finance and general securities and corporate matters covering a broad array of industries.
Since joining the firm, Frank has been instrumental in the development of its Capital Markets Group, with a particular focus on high-yield bonds and IPOs. He has represented various underwriters, initial purchasers, dealer managers and placement agents, including Bank of America Merrill Lynch, Citigroup, Credit Suisse, CRT Capital, Global Hunter Securities, Goldman Sachs, Imperial Capital, Jefferies, JMP Securities, JP Morgan, Lazard, Raymond James and UBS.
Chambers USA has lauded Frank for being "innovative in putting structures together and aggressive in getting deals done" and combining “exceptional technical expertise with a focus on business solutions." US Legal 500 has singled out Frank as “one of the sharpest corporate lawyers on Wall Street” and “one of the best capital markets attorneys in the nation with a wide ranging skill set in corporate finance, including initial public offerings, convertible bonds and high yield bonds.”
Peter J Marathas Jr
Peter Marathas is a Partner in the Employee Benefits, Executive Compensation & ERISA Litigation Practice Center and heads both the Employee Benefits Practice in the Boston office and Proskauer’s Health Care Reform Task Force.
As demonstrated by his “Band One” ranking in Chambers USA, Peter has a solid reputation as being among a short list of U.S. employee benefits lawyers who can guide his clients through complex federal and state benefits laws and tax, securities, ERISA and corporate governance issues in a sensible, efficient and understandable manner. Individual executives, management teams, boards and compensation committees in Boston, New York and across the U.S. recommend Peter as a go-to lawyer who provides clear advice on all matters related to the design and implementation of employee benefits and compensation programs.
Mr. Sachdev joined J.P. Morgan, a global investment bank, as a Managing Director in November 2010, and focuses on the healthcare services subsector. Previously, Mr. Sachdev was a Managing Director at Deutsche Bank Securities, Inc. (Deutsche Bank) from January 2009 and prior to that held the position of Director at Deutsche Bank from January 2007 until January 2009. Mr. Sachdev joined Deutsche Bank in 2006 as a Vice President. Prior to joining Deutsche Bank, Mr. Sachdev was a Vice President at Peter J. Solomon Company, an investment banking boutique, specializing in mergers and acquisitions in the healthcare sector, from 1998 to 2006.
Partner, Co-founder an the CEO of Rocket Science. Most recently, she spent four years as the EVP CFO of Vision-Sciences, a NASDAQ-listed medical device company in teh flexible endoscopy space. Prior to Vision-Sciences, she worked for over 15 years in healthcare investment banking, most recently at HSBC Securities where she was Head of MedTech Investment Banking.
Richard J. Zall
Richard Zall is Chair of the Health Care Department of Proskauer Rose LLP. His practice is focused on corporate and regulatory representation of a wide array of health care and life science clients, including academic medical centers, hospitals, physician organizations, information technology and medical device companies, managed care and health benefit management companies, and private equity firms.
Richard provides clients with counsel in the planning and execution of health care-related corporate transactions, including mergers and acquisitions, and equity and debt financings; the structuring of joint ventures and other contractual relationships among various health industry parties; and compliance with federal and state health care regulations. He also advises health care clients and health sector investors on business strategy, product and service development, financial transactions, and new venture implementation.
Over the past decade, Richard has been an active participant in the health care industry. He has directed two health industry studies for the Robert Wood Johnson Foundation, one on the condition of the U.S. health care safety net, and the other on Federal and State Consumer Protection Regulation of the Managed Care Industry.